Biphasic effects of insulin on islet amyloid polypeptide membrane disruption

Biophysical Journal

Volumn 100, Issue 3, 2011, Pages 685-692

  Brender, Jeffrey R ^b   Lee, Edgar L ^a   Hartman, Kevin ^b   Wong, Pamela T ^a   Ramamoorthy, Ayyalusamy ^b   Steel, Duncan G ^b   Gafni, Ari ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79551664256     PISSN: 00063495     EISSN: 15420086     Source Type: Journal    
DOI: 10.1016/j.bpj.2010.09.070     Document Type: Article

References (76)

1. Höppener, J. W. M., B. Ahrén, and C. J. M. Lips. 2000. Islet amyloid and type 2 diabetes mellitus. N. Engl. J. Med. 343:411-419.
2. Kahn, S. E., S. Andrikopoulos, and C. B. Verchere. 1999. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes. 48:241-253.
3. Hull, R. L., G. T. Westermark, S. E. Kahn. 2004. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J. Clin. Endocrinol. Metab. 89:3629-3643.
4. Harrison, R. S., P. C. Sharpe, D. P. Fairlie. 2007. Amyloid peptides and proteins in review. Rev. Physiol. Biochem. Pharmacol. 159:1-77.
5. Demuro, A., E. Mina, C. G. Glabe. 2005. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280:17294-17300.
6. Brender, J. R., K. Hartman, A. Ramamoorthy. 2008. A single mutation in the nonamyloidogenic region of islet amyloid polypeptide greatly reduces toxicity. Biochemistry. 47:12680-12688.
7. Esapa, C., J. H. Moffitt, A. Clark. 2005. Islet amyloid polypeptide gene promoter polymorphisms are not associated with type 2 diabetes or with the severity of islet amyloidosis. Biochim. Biophys. Acta. 1740:74-78.
8. Pildal, J., M. Lajer, O. Pedersen. 2003. Studies of variability in the islet amyloid polypeptide gene in relation to type 2 diabetes. Diabet. Med. 20:491-494.
9. Novials, A., I. Rojas, R. Gomis. 2001. A novel mutation in islet amyloid polypeptide (IAPP) gene promoter is associated with type II diabetes mellitus. Diabetologia. 44:1064-1065.
10. Sakagashira, S., H. J. Hiddinga, N. L. Eberhardt. 2000. Compared to wild-type human amylin, S20G mutant amylin exhibits increased cytotoxicity in transfected COS-1 cells and increased amyloidogenicity in vitro. Diabetes. 49, A401-A401.
11. Wei, L., P. Jiang, K. Pervushin. 2009. Residual structure in islet amyloid polypeptide mediates its interactions with soluble insulin. Biochemistry. 48:2368-2376.
12. Wiltzius, J. J., S. A. Sievers, D. Eisenberg. 2009. Atomic structures of IAPP (amylin) fusions suggest a mechanism for fibrillation and the role of insulin in the process. Protein Sci. 18:1521-1530.
13. Knight, J. D., J. A. Williamson, and A. D. Miranker. 2008. Interaction of membrane-bound islet amyloid polypeptide with soluble and crystalline insulin. Protein Sci. 17:1850-1856.
14. Larson, J. L., and A. D. Miranker. 2004. The mechanism of insulin action on islet amyloid polypeptide fiber formation. J. Mol. Biol. 335:221-231.
15. Gilead, S., H. Wolfenson, and E. Gazit. 2006. Molecular mapping of the recognition interface between the islet amyloid polypeptide and insulin. Angew. Chem. Int. Ed. Engl. 45:6476-6480.
16. Reference deleted in proof.
17. Kudva, Y. C., C. Mueske, N. L. Eberhardt. 1998. A novel assay in vitro of human islet amyloid polypeptide amyloidogenesis and effects of insulin secretory vesicle peptides on amyloid formation. Biochem. J. 331:809-813.
18. Jaikaran, E. T., M. R. Nilsson, and A. Clark. 2004. Pancreatic β-cell granule peptides form heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation. Biochem. J. 377:709-716.
19. Cui, W., J. W. Ma, Y. M. Li. 2009. Insulin is a kinetic but not a thermodynamic inhibitor of amylin aggregation. FEBS J. 276:3365-3371.
20. Sellin, D., L. M. Yan, R. Winter. 2010. Suppression of IAPP fibrillation at anionic lipid membranes via IAPP-derived amyloid inhibitors and insulin. Biophys. Chem. 150:73-79.
21. Reference deleted in proof.
22. Westermark, P., Z. C. Li, D. F. Steiner. 1996. Effects of β cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett. 379:203-206.
23. Janciauskiene, S., S. Eriksson, B. Ahrén. 1997. B cell granule peptides affect human islet amyloid polypeptide (IAPP) fibril formation in vitro. Biochem. Biophys. Res. Commun. 236:580-585.
24. Shoval, H., L. Weiner, D. Lichtenberg. 2008. Polyphenol-induced dissociation of various amyloid fibrils results in a methionine-independent formation of ROS. Biochim. Biophys. Acta. 1784:1570-1577.
25. Mamikonyan, G., M. Necula, M. G. Agadjanyan. 2007. Anti-Ab 1-11 antibody binds to different β-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J. Biol. Chem. 282:22376-22386.
26. Lambert, M. P., A. K. Barlow, W. L. Klein. 1998. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA. 95:6448-6453.
27. Oda, T., P. Wals, H. H. Osterburg, C. E. Finch. 1995. Clusterin (apoJ) alters the aggregation of amyloid β-peptide (A β 1-42) and forms slowly sedimenting A β complexes that cause oxidative stress. Exp. Neurol. 136:22-31.
28. Klein, W. L., G. A. Krafft, and C. E. Finch. 2001. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24:219-224.
29. Capone, R., F. G. Quiroz, M. Mayer. 2008. Amyloid-β ion channels in artificial lipid bilayers and neuronal cells. Neurotox. Res. 15:608-650.
30. Higham, C. E., E. T. Jaikaran, A. Clark. 2000. Preparation of synthetic human islet amyloid polypeptide (IAPP) in a stable conformation to enable study of conversion to amyloid-like fibrils. FEBS Lett. 470:55-60.
31. Stewart, J. C. 1980. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 104:10-14.
32. Engel, M. F. 2009. Membrane permeabilization by islet amyloid polypeptide. Chem. Phys. Lipids. 160:1-10.
33. Engel, M. F., L. Khemtémourian, J. W. Höppener. 2008. Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane. Proc. Natl. Acad. Sci. USA. 105:6033-6038.
34. Kayed, R., Y. Sokolov, C. G. Glabe. 2004. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279:46363-46366.
35. Mirzabekov, T. A., M. C. Lin, and B. L. Kagan. 1996. Pore formation by the cytotoxic islet amyloid peptide amylin. J. Biol. Chem. 271:1988-1992.
36. Sparr, E., M. F. M. Engel, J. A. Killian. 2004. Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers. FEBS Lett. 577:117-120.
37. Hebda, J. A., and A. D. Miranker. 2009. The interplay of catalysis and toxicity by amyloid intermediates on lipid bilayers: insights from type II diabetes. Annu. Rev. Biophys. 38:125-152.
38. Knight, J. D., J. A. Hebda, and A. D. Miranker. 2006. Conserved and cooperative assembly of membrane-bound α-helical states of islet amyloid polypeptide. Biochemistry. 45:9496-9508.
39. Rex, S., and G. Schwarz. 1998. Quantitative studies on the melittininduced leakage mechanism of lipid vesicles. Biochemistry. 37:2336-2345.
40. Schwarz, G., and C. H. Robert. 1992. Kinetics of pore-mediated release of marker molecules from liposomes or cells. Biophys. Chem. 42:291-296.
41. Almeida, P. F., and A. Pokorny. 2009. Mechanisms of antimicrobial, cytolytic, and cell-penetrating peptides: from kinetics to thermodynamics. Biochemistry. 48:8083-8093.
42. Gregory, S. M., A. Pokorny, and P. F. F. Almeida. 2009. Magainin 2 revisited: a test of the quantitative model for the all-or-none permeabilization of phospholipid vesicles. Biophys. J. 96:116-131.
43. Gregory, S. M., A. Cavenaugh, P. F. Almeida. 2008. A quantitative model for the all-or-none permeabilization of phospholipid vesicles by the antimicrobial peptide cecropin A. Biophys. J. 94:1667-1680.
44. Smith, P. E., J. R. Brender, and A. Ramamoorthy. 2009. Induction of negative curvature as a mechanism of cell toxicity by amyloidogenic peptides: the case of islet amyloid polypeptide. J. Am. Chem. Soc. 131:4470-4478.
45. Brender, J. R., U. H. N. Dürr, A. Ramamoorthy. 2007. Membrane fragmentation by an amyloidogenic fragment of human islet amyloid polypeptide detected by solid-state NMR spectroscopy of membrane nanotubes. Biochim. Biophys. Acta. 1768:2026-2029.
46. Domanov, Y. A., and P. K. J. Kinnunen. 2008. Islet amyloid polypeptide forms rigid lipid-protein amyloid fibrils on supported phospholipid bilayers. J. Mol. Biol. 376:42-54.
47. Treusch, S., D. M. Cyr, and S. Lindquist. 2009. Amyloid deposits: protection against toxic protein species? Cell Cycle. 8:1668-1674.
48. Khemtémourian, L., J. A. Killian, M. F. Engel. 2008. Recent insights in islet amyloid polypeptide-induced membrane disruption and its role in β-cell death in type 2 diabetes mellitus. Exp. Diabetes Res. 2008:421287.
49. Quist, A., I. Doudevski, R. Lal. 2005. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc. Natl. Acad. Sci. USA. 102:10427-10432.
50. Hirakura, Y., W. W. Yiu, B. L. Kagan. 2000. Amyloid peptide channels: blockade by zinc and inhibition by Congo red (amyloid channel block). Amyloid. 7:194-199.
51. Brender, J. R., E. L. Lee, A. Ramamoorthy. 2008. Amyloid fiber formation and membrane disruption are separate processes localized in two distinct regions of IAPP, the type-2-diabetes-related peptide. J. Am. Chem. Soc. 130:6424-6429.
52. Nanga, R. P. R., J. R. Brender, A. Ramamoorthy. 2008. Structures of rat and human islet amyloid polypeptide IAPP (1-19) in micelles by NMR spectroscopy. Biochemistry. 47:12689-12697.
53. Schauerte, J. A., P. T. Wong, A. Gafni. 2010. Simultaneous singlemolecule fluorescence and conductivity studies reveal distinct classes of Ab species on lipid bilayers. Biochemistry. 49:3031-3039.
54. Weise, K., D. Radovan, R. Winter. 2010. Interaction of hIAPP with model raft membranes and pancreatic β-cells: cytotoxicity of hIAPP oligomers. ChemBioChem. 11:1280-1290.
55. Anguiano, M., R. J. Nowak, and P. T. Lansbury, Jr. 2002. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a porelike mechanism that may be relevant to type II diabetes. Biochemistry. 41:11338-11343.
56. Porat, Y., S. Kolusheva, E. Gazit. 2003. The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry. 42:10971-10977.
57. Smith, D. P., D. J. Tew, R. Cappai. 2008. Formation of a high affinity lipid-binding intermediate during the early aggregation phase of α-synuclein. Biochemistry. 47:1425-1434.
58. El-Agnaf, O. M. A., S. Nagala, B. M. Austen. 2001. Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils. J. Mol. Biol. 310:157-168.
59. Shankar, G. M., S. M. Li, D. J. Selkoe. 2008. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14:837-842.
60. Townsend, M., G. M. Shankar, D. J. Selkoe. 2006. Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 572:477-492.
61. Cleary, J. P., D. M. Walsh, K. H. Ashe. 2005. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci. 8:79-84.
62. Bitan, G., A. Lomakin, and D. B. Teplow. 2001. Amyloid β-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J. Biol. Chem. 276:35176-35184.
63. Gong, Y., L. Chang, W. L. Klein. 2003. Alzheimer's diseaseaffected brain: presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA. 100:10417-10422.
64. Huang, T. H. J., D. S. Yang, A. Chakrabartty. 2000. Structural studies of soluble oligomers of the Alzheimer β-amyloid peptide. J. Mol. Biol. 297:73-87.
65. Lesné, S., M. T. Koh, K. H. Ashe. 2006. A specific amyloidb protein assembly in the brain impairs memory. Nature. 440:352-357.
66. Hepler, R. W., K. M. Grimm, J. G. Joyce. 2006. Solution state characterization of amyloid β-derived diffusible ligands. Biochemistry. 45:15157-15167.
67. Soong, R., J. R. Brender, A. Ramamoorthy. 2009. Association of highly compact type II diabetes related islet amyloid polypeptide intermediate species at physiological temperature revealed by diffusion NMR spectroscopy. J. Am. Chem. Soc. 131:7079-7085.
68. Engel, M. F. M., H. Yigittop, J. Antoinette Killian. 2006. Islet amyloid polypeptide inserts into phospholipid monolayers as monomer. J. Mol. Biol. 356:783-789.
69. Vaiana, S. M., R. Ghirlando, J. Hofrichter. 2008. Sedimentation studies on human amylin fail to detect low-molecular-weight oligomers. Biophys. J. 94: L45-L47.
70. Rustenbeck, I., A. Matthies, and S. Lenzen. 1994. Lipid composition of glucose-stimulated pancreatic islets and insulin-secreting tumor cells. Lipids. 29:685-692.
71. Knight, J. D., and A. D. Miranker. 2004. Phospholipid catalysis of diabetic amyloid assembly. J. Mol. Biol. 341:1175-1187.
72. Schengrund, C. L. 2010. Lipid rafts: keys to neurodegeneration. Brain Res. Bull. 82:7-17.
73. Cho, W. J., S. Trikha, and A. M. Jeremic. 2009. Cholesterol regulates assembly of human islet amyloid polypeptide on model membranes. J. Mol. Biol. 393:765-775.
74. Matveyenko, A. V., T. Gurlo, P. C. Butler. 2009. Successful versus failed adaptation to high-fat diet-induced insulin resistance: the role of IAPP-induced β-cell endoplasmic reticulum stress. Diabetes. 58:906-916.
75. Abedini, A., and D. P. Raleigh. 2005. The role of His-18 in amyloid formation by human islet amyloid polypeptide. Biochemistry. 44:16284-16291.
76. Jaikaran, E. T., C. E. Higham, P. E. Fraser. 2001. Identification of a novel human islet amyloid polypeptide β-sheet domain and factors influencing fibrillogenesis. J. Mol. Biol. 308:515-525.